We use cookies to give you the best possible experience on our website.

The challenges we face

Companies, especially SMEs, can face significant challenges to introduce their new and innovative products into the NHS. The complexity of public procurement, patient safety and a risk averse culture across multiple organisations can be daunting. The Innovation Nexus aims to provide a single source of resource that can help companies, particularly SMEs, understand the steps that need to be taken to support their business planning and engage with the NHS more easily, thus progressing the adoption of their innovation at pace and with fewer unanticipated obstacles.

a fully funded intensive support programme for life science SMEs working in Greater Manchester

How can the Innovation Nexus help me?

Speak directly to a GM AHSN advisor with NHS expertise

Help with navigating NHS procurement

Information about funding and investment

Help with setting up a trial of your innovation

Information on science parks and office locations

Connect you with relevant organisations

 

Free industry support from NHS experts

If you are a business with an innovative product or service that you believe has the potential to benefit the healthcare market, the Innovation Nexus can give you access a network of specialist advice and support.

Subscribe to our mailing list

* indicates required

Asset Publisher Asset Publisher

Back

ZedScan™ delivers significant increase in HG CIN detection rates across all high risk HPV positive women

A review into the management of more than 800 women referred to an NHS colposcopy clinic who were positive for high risk HPV (hrHPV) has revealed a substantial increase in detection of high grade cervical intraepithelial neoplasia (HG CIN) following the adoption of ZedScan into routine use. 
As one of the sentinel sites for primary HPV screening, clinicians at Sheffield Teaching Hospitals NHS Foundation Trust’s (STH) used ZedScan alongside colposcopy over a period of two years and assessed the impact on clinical performance relative to HPV genotype. 
Inclusion of ZedScan delivered higher rates of disease detection in all hrHPV positive women and non-HPV 16 cases in particular, compared with colposcopy alone. 
The clinicians consequently concluded that the ability of ZedScan to detect HG CIN is not influenced by the HPV genotype. 
Professor Tidy, clinical founder of Zilico Ltd and consultant gynaecological oncologist at STH, said: “ZedScan compensates for the reliance on acetowhite change to identify disease and this will be increasingly critical as the prevalence of HPV16 and 18 falls in the vaccinated population.” 
Zilico Ltd were supported through the NHS procurement process by GM AHSN, enabling them to get their product distributed in Sheffield Teaching Hospitals NHS Trust.